A comparison of the anti-tumor effects of a chimeric Versus murine anti-CD19 immunotoxins on human B cell lymphoma and pre-B acute lymphoblastic leukemia cell lines

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Precursor B cell acute lymphoblastic leukemia (pre-B ALL) affects five to six thousand adults and almost three thousand children every year. Approximately 25% of the children and 60% of the adults die from their disease, highlighting the need for new therapies that complement rather than overlap chemotherapy and bone marrow transplantation. Immunotherapy is a class of therapies where toxicities and mechanisms of action do not overlap with those of chemotherapy. Because CD19 is a B cell- restricted membrane antigen that is expressed on the majority of pre-B tumor cells, a CD19-based immunotherapy is being developed for ALL. In this study, the anti-tumor activities of immunotoxins (ITs) constructed by conjugating a murine monoclonal antibody (MAb), HD37, or its chimeric (c) construct to recombinant ricin toxin A chain (rRTA) were compared both in vitro using human pre-B ALL and Burkitt's lymphoma cell lines and in vivo using a disseminated human pre-B ALL tumor cell xenograft model. The murine and chimeric HD37 IT constructs were equally cytotoxic to pre-B ALL and Burkitt's lymphoma cells in vitro and their use in vivo resulted in equivalent increases in survival of SCID mice with human pre-B ALL tumors when compared with control mice.

Original languageEnglish (US)
Pages (from-to)409-419
Number of pages11
JournalToxins
Volume3
Issue number4
DOIs
StatePublished - Apr 1 2011

Keywords

  • Anti-CD19
  • Chimerization
  • Ricin A chain

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Fingerprint Dive into the research topics of 'A comparison of the anti-tumor effects of a chimeric Versus murine anti-CD19 immunotoxins on human B cell lymphoma and pre-B acute lymphoblastic leukemia cell lines'. Together they form a unique fingerprint.

  • Cite this